BR112022013646A2 - Método de tratamento de esplenomegalia - Google Patents

Método de tratamento de esplenomegalia

Info

Publication number
BR112022013646A2
BR112022013646A2 BR112022013646A BR112022013646A BR112022013646A2 BR 112022013646 A2 BR112022013646 A2 BR 112022013646A2 BR 112022013646 A BR112022013646 A BR 112022013646A BR 112022013646 A BR112022013646 A BR 112022013646A BR 112022013646 A2 BR112022013646 A2 BR 112022013646A2
Authority
BR
Brazil
Prior art keywords
splenomegaly
treatment
methods
therapeutic methods
certain embodiments
Prior art date
Application number
BR112022013646A
Other languages
English (en)
Inventor
Philip Rothbaum Wayne
Original Assignee
Telios Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telios Pharma Inc filed Critical Telios Pharma Inc
Publication of BR112022013646A2 publication Critical patent/BR112022013646A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Processing Of Solid Wastes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

MÉTODOS DE TRATAMENTO DE ESPLENOMEGALIA. São descritos métodos terapêuticos e composições farmacêuticas para o tratamento de esplenomegalia em um sujeito humano. Em certas modalidades, a invenção inclui métodos terapêuticos de tratamento de esplenomegalia usando um inibidor de BTK.
BR112022013646A 2020-01-08 2021-01-08 Método de tratamento de esplenomegalia BR112022013646A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062958632P 2020-01-08 2020-01-08
PCT/US2021/012696 WO2021142257A1 (en) 2020-01-08 2021-01-08 Methods of treating splenomegaly

Publications (1)

Publication Number Publication Date
BR112022013646A2 true BR112022013646A2 (pt) 2022-10-04

Family

ID=76788747

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022013646A BR112022013646A2 (pt) 2020-01-08 2021-01-08 Método de tratamento de esplenomegalia

Country Status (14)

Country Link
EP (2) EP3980069A4 (pt)
JP (1) JP2023509968A (pt)
KR (1) KR20220130151A (pt)
CN (1) CN114423457A (pt)
AU (1) AU2021205484A1 (pt)
BR (1) BR112022013646A2 (pt)
CA (1) CA3164063A1 (pt)
CO (1) CO2022010592A2 (pt)
CR (1) CR20220374A (pt)
IL (1) IL294582A (pt)
JO (1) JOP20220168A1 (pt)
MA (1) MA57226B1 (pt)
MX (1) MX2022008490A (pt)
WO (1) WO2021142257A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240024314A1 (en) 2020-01-08 2024-01-25 Telios Pharma, Inc. Methods of Treating Splenomegaly
CR20220374A (es) * 2020-01-08 2023-01-25 Telios Pharma Inc Métodos de tratamiento de la esplenomegalia
WO2023071973A1 (en) * 2021-10-26 2023-05-04 Shenzhen Targetrx, Inc. Fused bicyclic compound for inhibiting activity of tyrosine kinase
WO2024041614A1 (en) * 2022-08-25 2024-02-29 Beigene Switzerland Gmbh Solid forms comprising (s) -7- (1-acryloylpiperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahydropyrazolo [1, 5-a] pyrimidine-3-carboxamide, and oxalic acid, compositions and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015057992A1 (en) * 2013-10-16 2015-04-23 Izumi Raquel Btk inhibitors for hematopoietic mobilization
HUE056329T2 (hu) * 2014-08-11 2022-02-28 Acerta Pharma Bv BTK-inhibitor és BCL-2-inhibitor terápiás kombinációi
US9708348B2 (en) * 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
MX2020013321A (es) * 2018-06-19 2021-02-22 Merck Patent Gmbh Nuevas formas cristalinas de 1-(4-{[6-amino-5-(4-fenoxi-fenil)-pir imidin-4-ilamino]-metil}-4-fluoro-piperidin-1-il)-propenona, formas de sal de la misma y procesos de obtencion.
TW202128156A (zh) * 2019-11-14 2021-08-01 美商夸格智財控股有限公司 用於癌症治療之btk抑制劑及mdm2抑制劑之組合
CR20220374A (es) * 2020-01-08 2023-01-25 Telios Pharma Inc Métodos de tratamiento de la esplenomegalia

Also Published As

Publication number Publication date
MX2022008490A (es) 2022-10-13
IL294582A (en) 2022-09-01
AU2021205484A1 (en) 2022-08-18
EP3980069A4 (en) 2022-08-17
JOP20220168A1 (ar) 2023-01-30
CO2022010592A2 (es) 2022-10-31
MA57226A1 (fr) 2023-02-28
CR20220374A (es) 2023-01-25
MA57226B1 (fr) 2023-06-28
EP4000624A1 (en) 2022-05-25
CN114423457A (zh) 2022-04-29
KR20220130151A (ko) 2022-09-26
CA3164063A1 (en) 2021-07-15
WO2021142257A1 (en) 2021-07-15
EP3980069A1 (en) 2022-04-13
JP2023509968A (ja) 2023-03-10

Similar Documents

Publication Publication Date Title
BR112022013646A2 (pt) Método de tratamento de esplenomegalia
EA201892510A2 (ru) Комбинированная терапия для лечения рака
EA202091846A1 (ru) Соединения с активностью, индуцирующей ферроптоз, и способы их применения
BR112018007656A2 (pt) terapia de combinação para tratamento de doenças malignas
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
BR112018074152A2 (pt) métodos para determinar um regime de dosagem, métodos para tratar um indivíduo, método para otimizar o tratamento terapeuticamente, agente terapêutico e sistema de rede para determinar uma dose eficaz ou um regime de dosagem para um indivíduo sendo tratado com um agente terapêutico
MX2021011110A (es) Tratamiento de ataque de angioedema hereditario con dosis reducida de anticuerpos que se unen a calicreína plasmática humana.
EA201892803A1 (ru) Противоопухолевая терапия
CY1124123T1 (el) Φαρμακευτικοι συνδυασμοι για θεραπεια καρκινου
WO2018102687A3 (en) Combination therapy for treating cancer
CO2020014599A2 (es) Métodos para tratar cáncer
MX2021002349A (es) Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario.
CL2022000214A1 (es) Inhibidores de enzimas
CY1123696T1 (el) Φαρμακο για τη θεραπεια των μολυνσεων του διαβητικου ποδιου
BR112021017550A2 (pt) Métodos de tratamento da amiloidose al
CL2022001458A1 (es) Método para el tratamiento de cáncer utilizando célula ad-yuvante artificial (aavc)
CR20210514A (es) USO DE REBOXETINA PARA EL TRATAMIENTO DE NARCOLEPSIA (Divisional 2021-0183)
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
BR112018014762A2 (pt) método de tratamento da doença de alzheimer (da) precoce
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
MX2021008716A (es) Metodo para tratar dolor de osteoartritis al administrar resiniferatoxina.
EA202091653A1 (ru) Миноциклин для лечения воспалительных заболеваний кожи
EA202190226A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.
BR112018076935A2 (pt) composição, medicamento e método para o tratamento da alopecia induzida por quimioterapia